← Back to ARE.PRD filing summaryOriginal filing text · Part II
Item 1 — Legal Proceedings
Alexandria Real Estate Equities, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
Stockholder Matters
On November 25, 2025, a securities class action was filed against the Company and certain of its officers and directors in the
United States District Court for the Central District of California. The operative complaint alleges violations of the federal securities laws
based on alleged material misrepresentations and omissions related to the Company’s business performance and real estate
impairment charges. The complaint seeks damages and other relief on behalf of investors who acquired the Company’s securities
between January 30, 2024 and December 5, 2025. The defendants moved to dismiss the action on May 20, 2026.
On February 3, 2026, March 25, 2026, and June 25, 2026, stockholder derivative actions were filed against certain officers and
directors of the Company, with the Company named as a nominal defendant, in the United States District Court for the District of
Maryland and the United States District Court for the Central District of California. The derivative complaints assert claims under the
federal securities laws and state law based on allegations similar to those in the securities class action and seek damages and other
relief on behalf of the Company. The first two derivative actions were stayed on April 8, 2026 and June 23, 2026, respectively, pending
resolution of any motion to dismiss in the securities class action.
The Company does not believe the complaints state any meritorious claims and intends to defend these cases vigorously.
At this time, we cannot predict the outcome of these matters or reasonably estimate the amount or range of any possible loss,
if any, and therefore we have not recorded an accrual related to these matters.
Option Parcel Development at Alexandria Center® for Life Science – New York City Campus
Refer to “Other” in Note 3 – “Investments in real estate” to our unaudited consolidated financial statements for information
regarding litigation involving our subsidiary in connection with an option and ground lease for a development parcel at the Alexandria
Center® for Life Science – New York City campus.